Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 24 2025
0mins
Source: Globenewswire
Positive Clinical Trial Results: Aura Biosciences presented promising Phase 1 trial data for its treatment bel-sar in non-muscle invasive bladder cancer (NMIBC) and initiated a Phase 2 trial for metastases to the choroid, indicating potential as a front-line therapy across multiple oncology indications.
Financial Overview: The company reported a net loss of $86.9 million for 2024, with sufficient cash reserves expected to support operations into the second half of 2026, while continuing to advance its clinical pipeline and expand its research efforts.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
